Xilio Therapeutics, Inc.
XLO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XLO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XLO
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-selective immunotherapies using its proprietary masking technology, with a focus on advancing its lead candidates efarindodekin alfa and XTX501 through early-stage clinical trials.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Xilio Therapeutics, Inc..
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-selective immunotherapies using its proprietary masking technology, with a focus on advancing its lead candidates efarindodekin alfa and XTX501 through early-stage clinical trials.
- Xilio's proprietary masking technology aims to enable tumor-selective activity of immunotherapies, potentially reducing systemic toxicity [sec_mda · as of 2026-05-12].
- The company has established strategic partnerships with AbbVie and Gilead, including a $6.0 million development milestone achieved under the AbbVie collaboration in Q2 2026 [sec_mda · as of 2026-08-12].
- As of June 30, 2026, Xilio had cash and cash equivalents of $136.0 million, with an accumulated deficit of $434.7 million [sec_mda · as of 2026-08-12].
- The company reported a net loss of $35.0 million for the year ended December 31, 2025, and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-12].
- Xilio's cash runway is projected to fund operations into the first quarter of 2028, excluding potential additional proceeds from warrant exercises or milestone payments [sec_mda · as of 2026-08-12].
What works
- Proprietary masking technology is clinically validated and has enabled partnerships with major pharma companies like AbbVie and Gilead [sec_mda · as of 2026-05-12].
- Cash position of $136.0 million as of June 30, 2026, together with a $6.0 million milestone, is expected to fund operations into Q1 2028 [sec_mda · as of 2026-08-12].
- Collaboration with AbbVie generated a $6.0 million development milestone in Q2 2026, demonstrating partnership progress [sec_mda · as of 2026-08-12].
What to weigh
- Xilio has not yet commercialized any product candidates and does not expect to generate product revenue for several years, if at all [sec_mda · as of 2026-08-12].
- The company has an accumulated deficit of $434.7 million as of June 30, 2026, and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-12].
- All product candidates are in preclinical or early clinical development, with no approved therapies, making the company highly dependent on clinical trial success [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Xilio's masking technology is clinically validated and supports partnerships with AbbVie and Gilead.
“masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.”
SEC MD&A · May 12, 2026
Cash and cash equivalents as of June 30, 2026, were $136.0 million.
“As of June 30, 2026, we had cash and cash equivalents of $136.0 million.”
SEC MD&A · August 12, 2026
Accumulated deficit as of June 30, 2026, was $434.7 million.
“As of June 30, 2026, we had an accumulated deficit of $434.7 million.”
SEC MD&A · August 12, 2026
Xilio has not commercialized any product candidates and does not expect product revenue for several years.
“We have not yet commercialized any of our product candidates, which are in preclinical or early clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- No approved products — All product candidates are in preclinical or early clinical stages; no commercial revenue expected for years [sec_mda · as of 2026-08-12].
- Significant accumulated deficit — Accumulated deficit of $434.7 million as of June 30, 2026, with ongoing operating losses [sec_mda · as of 2026-08-12].
- Dependence on partnerships — Future funding relies on milestones and options from AbbVie and Gilead, which may not materialize [sec_mda · as of 2026-08-12].
- Clinical trial uncertainty — Success of efarindodekin alfa and XTX501 trials is uncertain; failure could impact viability [sec_mda · as of 2026-08-12].
What to watch
- Progress of clinical trials for efarindodekin alfa and XTX501, as these are key value drivers [sec_mda · as of 2026-08-12].
- Achievement of additional milestones under the AbbVie and Gilead collaborations, which could extend cash runway [sec_mda · as of 2026-08-12].
- Exercise of Series C warrants, which could provide up to $36.2 million in additional gross proceeds [sec_mda · as of 2026-08-12].
- Updates on cash burn rate and any changes to the projected runway into Q1 2028 [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Xilio Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xilio Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.4 months
D/E 1.13
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$5.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 247,320 | $2.1M |
| caligan partners lp | 112,128 | $943K |
| morgan stanley | 57,493 | $484K |
| renaissance technologies llc | 49,566 | $417K |
| aju ib investment co., ltd. | 47,695 | $401K |
| geode capital management, llc | 37,197 | $313K |
| fmr llc | 36,558 | $307K |
| vanguard fiduciary trust co | 28,475 | $239K |
| velan capital investment management lp | 14,285 | $120K |
| ghisallo capital management llc | 13,800 | $116K |
Showing top 10 of 18 institutional holders of Xilio Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.8%
- Days to cover
- 3.8
- Shares short
- 174,319
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XLO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xilio Therapeutics, Inc.?
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-selective immunotherapies using its proprietary masking technology, with a focus on advancing its lead candidates efarindodekin alfa and XTX501 through early-stage clinical trials.
What is Xilio Therapeutics, Inc.'s lead drug candidate?
Xilio Therapeutics, Inc.'s most advanced tracked candidate is vilastobart (Phase 1/Phase 2) for Advanced Solid Tumor.
Who is the CEO of Xilio Therapeutics, Inc.?
Dr. Rene Russo BCPS, Pharm.D. is the chief executive officer of Xilio Therapeutics, Inc. (XLO).
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. (XLO) is headquartered in Waltham, MA, United States.
What therapeutic areas does Xilio Therapeutics, Inc. focus on?
Xilio Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.